David Altshuler - Jul 19, 2022 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, Global Research and CSO
Signature
/s/ Joy Liu, Attorney-in-Fact
Stock symbol
VRTX
Transactions as of
Jul 19, 2022
Transactions value $
-$2,059,782
Form type
4
Date filed
7/21/2022, 04:48 PM
Previous filing
Feb 28, 2022
Next filing
Aug 10, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Options Exercise $1.96M +10.4K +28.82% $187.53 46.6K Jul 19, 2022 Direct F1
transaction VRTX Common Stock Options Exercise $1.14M +7.34K +15.75% $155.57 53.9K Jul 19, 2022 Direct
transaction VRTX Common Stock Sale -$276K -963 -1.79% $286.72 53K Jul 19, 2022 Direct F2, F3, F4
transaction VRTX Common Stock Sale -$1.31M -4.56K -8.61% $287.83 48.4K Jul 19, 2022 Direct F2, F3, F5
transaction VRTX Common Stock Sale -$1.66M -5.74K -11.85% $288.67 42.7K Jul 19, 2022 Direct F2, F3, F6
transaction VRTX Common Stock Sale -$1.91M -6.6K -15.47% $289.48 36.1K Jul 19, 2022 Direct F2, F3, F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRTX Stock Option (Right to Buy) Options Exercise $0 -10.4K -72.72% $0.00 3.91K Jul 19, 2022 Common Stock 10.4K $187.53 Direct F8
transaction VRTX Stock Option (Right to Buy) Options Exercise $0 -7.34K -100% $0.00* 0 Jul 19, 2022 Common Stock 7.34K $155.57 Direct F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 100 shares previously purchased under the issuer's Employee Stock Purchase Plan.
F2 Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1.
F3 Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4 Open market sales reported on this line occurred at a weighted average price of $286.72 (range $286.07 to $287.01).
F5 Open market sales reported on this line occurred at a weighted average price of $287.83 (range $287.11 to $288.10).
F6 Open market sales reported on this line occurred at a weighted average price of $288.67 (range $288.11 to $289.09).
F7 Open market sales reported on this line occurred at a weighted average price of $289.48 (range $289.11 to $290.06).
F8 The option vests in 16 quarterly installments from 2/6/2019.
F9 Fully vested.